Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer

Ursula M Vogl; Irene Testi; Maria De Santis

doi:10.1016/j.euf.2024.03.005

Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer

Eur Urol Focus. 2024 Apr 5:S2405-4569(24)00049-X. doi: 10.1016/j.euf.2024.03.005. Online ahead of print.

Authors

Ursula M Vogl¹, Irene Testi², Maria De Santis³

Affiliations

¹ Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland. Electronic address: ursula.vogl@eoc.ch.
² Oncology Institute of Southern Switzerland EOC, Bellinzona, Switzerland; Medical Oncology Unit, University Hospital Parma, Parma, Italy.
³ Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University Vienna, Austria.

PMID: 38582643
DOI: 10.1016/j.euf.2024.03.005

Abstract

Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.